MICROBA LIFE SCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.175 AUD | 0.00% |
|
-5.41% | -2.78% |
| 04-23 | Microba's Revenue Climbs 297% in Fiscal Q3 | MT |
| 04-10 | Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5% | MT |
Valuation
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 54.87 | 103.2 | 78.37 | - | - |
| Enterprise Value (EV) 1 | 25.62 | 72.33 | 57.92 | 61.31 | 71.12 |
| P/E ratio | -3.89 x | -7.44 x | -4.49 x | -4.57 x | -10 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 11.7 x | 19 x | 6.64 x | 4.36 x | 2.28 x |
| EV / Revenue | 5.46 x | 13.3 x | 4.9 x | 3.41 x | 2.07 x |
| EV / EBITDA | -2.6 x | -6.59 x | -3.44 x | -3.95 x | -8.83 x |
| EV / FCF | -2.08 x | - | -3.49 x | -5.29 x | - |
| FCF Yield | -48.1% | - | -28.7% | -18.9% | - |
| Price to Book | 1.64 x | 2.68 x | 1.88 x | 3.02 x | 3.18 x |
| Nbr of stocks (in thousands) | 274,358 | 344,136 | 447,852 | - | - |
| Reference price 2 | 0.2000 | 0.3000 | 0.1750 | 0.1750 | 0.1750 |
| Announcement Date | 25/08/22 | 29/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 4.689 | 5.42 | 11.81 | 17.97 | 34.38 |
| EBITDA 1 | - | -9.863 | -10.97 | -16.86 | -15.54 | -8.055 |
| EBIT 1 | - | -11.41 | -12.61 | -18.45 | -17.07 | -9.65 |
| Operating Margin | - | -243.27% | -232.73% | -156.22% | -94.99% | -28.06% |
| Earnings before Tax (EBT) 1 | - | -11.46 | -12.67 | -17.25 | -17.13 | -9 |
| Net income 1 | -7.524 | -11.47 | -12.68 | -17.25 | -16.63 | -9 |
| Net margin | - | -244.64% | -233.95% | -146.06% | -92.58% | -26.17% |
| EPS 2 | -0.0370 | -0.0514 | -0.0403 | -0.0390 | -0.0383 | -0.0175 |
| Free Cash Flow 1 | - | -12.32 | - | -16.6 | -11.6 | - |
| FCF margin | - | -262.8% | - | -140.56% | -64.56% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 01/04/22 | 25/08/22 | 29/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|
| Net sales 1 | 2.49 | 2.152 | - | 3.273 | 8.6 |
| EBITDA 1 | -4.544 | - | - | -10.94 | -7.3 |
| EBIT | -5.402 | -5.795 | - | - | - |
| Operating Margin | -216.97% | -269.34% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income 1 | -5.44 | -5.679 | -7.001 | - | -7.8 |
| Net margin | -218.49% | -263.96% | - | - | -90.7% |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 25/08/22 | 22/02/23 | 29/08/23 | 27/02/24 | - |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 29.3 | 30.9 | 20.5 | 17.1 | 7.25 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -12.3 | - | -16.6 | -11.6 | - |
| ROE (net income / shareholders' equity) | - | -47.3% | - | -60.6% | -44.3% | - |
| ROA (Net income/ Total Assets) | - | -39.6% | - | -39.6% | -28.7% | - |
| Assets 1 | - | 28.98 | - | 43.56 | 57.96 | - |
| Book Value Per Share 2 | - | 0.1200 | 0.1100 | 0.0900 | 0.0600 | 0.0600 |
| Cash Flow per Share 2 | - | -0.0500 | - | -0.0400 | -0.0300 | -0.0300 |
| Capex 1 | - | 1.87 | 3.04 | 0.85 | 1.13 | 0.7 |
| Capex / Sales | - | 39.94% | 56.03% | 7.2% | 6.31% | 2.04% |
| Announcement Date | 01/04/22 | 25/08/22 | 29/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.175
AUD
Average target price
0.38
AUD
Spread / Average Target
+117.14%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.78% | 51.79M | |
| -16.58% | 8.44B | |
| +54.07% | 3.96B | |
| -37.54% | 2.52B | |
| -10.51% | 2.44B | |
| -8.91% | 2.22B | |
| -4.20% | 1.98B | |
| -18.24% | 1.58B | |
| -36.41% | 1.3B | |
| +2.19% | 1.05B |
- Stock Market
- Equities
- MAP Stock
- Financials Microba Life Sciences Limited
